- Home
- PNI vs PSNL Comparison
PNI vs PSNL Comparison
Compare PNI & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PNI | PSNL |
|---|---|---|
| Founded | 2002 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.9M | 872.1M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | PNI | PSNL |
|---|---|---|
| Price | $6.89 | $8.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $10.71 |
| AVG Volume (30 Days) | 26.4K | ★ 1.7M |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 4.76% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $69,103,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $20.33 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.03 | $2.83 |
| 52 Week High | $7.89 | $11.40 |
Technical Indicators
Market Signals| Indicator | PNI | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 47.74 | 45.93 |
| Support Level | $6.82 | $7.68 |
| Resistance Level | $6.94 | $9.10 |
| Average True Range (ATR) | 0.05 | 0.57 |
| MACD | 0.00 | -0.14 |
| Stochastic Oscillator | 49.67 | 26.95 |
Price Performance
Historical ComparisonAbout PNI Pimco New York Municipal Income Fund II of Beneficial Interest
PIMCO New York Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State and New York City income tax. The fund portfolio of investments consists of investments in different sectors such as education, transportation, healthcare, and others.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.